Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Open in API
Filings indexed 437 across all filing types
Latest filing 2022-08-29 Report Publication Anno…
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow and conference call). It provides details such as the date, location, purpose, and contact information for the event. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a general regulatory filing/announcement.
2022-08-29 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it is a short regulatory notice, it falls under the category of a general regulatory filing or announcement regarding corporate activities.
2022-08-29 Korean
기타시장안내(개선기간 종료에 따른 상장폐지여부 결정 안내)
Delisting Announcement Classification · 100% confidence The document is a regulatory notice from the stock exchange regarding the status of a company's listing (Qurient) following the end of an improvement period. It outlines the timeline for submitting documentation and the subsequent review process by the Corporate Review Committee. Since it is a regulatory announcement regarding listing status and does not fit into specific categories like 'Delisting Announcement' (as it is a procedural update on the review process rather than a final delisting notice) or 'Legal Proceedings', it falls under the general regulatory filing category.
2022-08-17 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company '주식회사 큐리언트' covering the period from 2022-01-01 to 2022-06-30. It contains detailed financial information, business operations, and management analysis, which fits the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-16 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details a revision to a previously disclosed contract amount due to actual research expenses incurred. Since this is a specific regulatory disclosure regarding a contract amendment and does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2022-07-15 Korean
투자판단관련주요경영사항(면역항암제 Q702와 Pembrolizumab(키투르다) 병용투여에 관한 한국 식품의약품안전처(MFDS) 임상 제1B/2상 시험계획(IND) 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (Curacle) submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding the submission of an Investigational New Drug (IND) application for a clinical trial (Phase 1B/2) to the Ministry of Food and Drug Safety (MFDS). Since this is a specific regulatory disclosure of a material event (clinical trial progress) that does not fit into categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' category.
2022-07-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.